Itraconazole
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Antifungals | Itraconazole | 100-200mg PO Q24H | Administer Anytime During HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 706 | 35 | 21 | 25 | 99 | 10 | N/A | 0 (high flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- Boelaert J, Schurgers M, Matthys E et al. Itraconazole Pharmacokinetics in Patients with Renal Dysfunction. Antimicrobial agents and chemotherapy 1988; 32(10), 1595-8.
- Cota J, Burgess D. Antifungal Dose Adjustment in Renal and Hepatic Dysfunction : Pharmacokinetic and Pharmacodynamic Considerations. Curr Fungal Infect Rep 2010; 4, 120-128.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB01167
- Gandhi B, Bahadur M, Dodeja H, Aggrwal V, Thamba A, Mali M. Systemic fungal infections in renal diseases. Journal of postgraduate medicine 2005; 51(Suppl 1), S30-6.
- Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
- Mohr J, Finkel K, Rex J et al. Pharmacokinetics of Intravenous Itraconazole in Stable Hemodialysis Patients. Antimicrobial agents and chemotherapy 2004; 48(8), 3151-4.